Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Interpace Biosciences Inc is a diagnostics & research business based in the US. Interpace Biosciences shares (IDXG) are listed on the OTCQX (a marketplace for buying and selling "over the counter" stocks which aren't listed on a formal stock exchange) and all prices are listed in US Dollars. Interpace Biosciences employs 152 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.70|
|52-week range||$2.82 - $10.51|
|50-day moving average||$8.87|
|200-day moving average||$8.87|
|Wall St. target price||$11.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.42|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||2.35%|
|1 month (2021-09-20)||-1.14%|
|3 months (2021-07-20)||4.82%|
|6 months (2021-04-20)||8.75%|
|1 year (2020-10-19)||118.05%|
|2 years (2019-10-18)||987.77%|
|3 years (2018-10-19)||539.71%|
|5 years (2016-10-19)||5,950.07%|
|Revenue TTM||$38.9 million|
|Gross profit TTM||$10.7 million|
|Return on assets TTM||-23.15%|
|Return on equity TTM||-105.93%|
|Market capitalisation||$35.5 million|
TTM: trailing 12 months
There are currently 47,355 Interpace Biosciences shares held short by investors – that's known as Interpace Biosciences's "short interest". This figure is 58.9% up from 29,806 last month.
There are a few different ways that this level of interest in shorting Interpace Biosciences shares can be evaluated.
Interpace Biosciences's "short interest ratio" (SIR) is the quantity of Interpace Biosciences shares currently shorted divided by the average quantity of Interpace Biosciences shares traded daily (recently around 249236.84210526). Interpace Biosciences's SIR currently stands at 0.19. In other words for every 100,000 Interpace Biosciences shares traded daily on the market, roughly 190 shares are currently held short.
However Interpace Biosciences's short interest can also be evaluated against the total number of Interpace Biosciences shares, or, against the total number of tradable Interpace Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Interpace Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Interpace Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0136% of the tradable shares (for every 100,000 tradable Interpace Biosciences shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Interpace Biosciences.
Find out more about how you can short Interpace Biosciences stock.
We're not expecting Interpace Biosciences to pay a dividend over the next 12 months.
Interpace Biosciences's shares were split on a 1:10 basis on 14 January 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Interpace Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Interpace Biosciences shares which in turn could have impacted Interpace Biosciences's share price.
Over the last 12 months, Interpace Biosciences's shares have ranged in value from as little as $2.82 up to $10.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQX average) beta is 1, while Interpace Biosciences's is 1.1873. This would suggest that Interpace Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.